Gunnarsson I - Search Results

1

De novo lupus nephritis during treatment with belimumab.

Parodis I, Vital EM, Hassan SU, Jönsen A, Bengtsson AA, Eriksson P, Leonard D, Gunnarsson I, Rönnblom L, Sjöwall C. Parodis I, et al. Among authors: gunnarsson i. Rheumatology (Oxford). 2021 Sep 1;60(9):4348-4354. doi: 10.1093/rheumatology/keaa796. Rheumatology (Oxford). 2021. PMID: 33341888 Free PMC article.

2

Olsalazine-induced lupus syndrome.

Gunnarsson I, Pettersson E, Lindblad S, Ringertz B. Gunnarsson I, et al. Scand J Rheumatol. 1997;26(1):65-6. doi: 10.3109/03009749709065668. Scand J Rheumatol. 1997. PMID: 9057806

3

Association between ongoing anti-C1q antibody production in peripheral blood and proliferative nephritis in patients with active systemic lupus erythematosus.

Gunnarsson I, Rönnelid J, Huang YH, Rogberg S, Nilsson B, Lundberg I, Klareskog L. Gunnarsson I, et al. Br J Rheumatol. 1997 Jan;36(1):32-7. doi: 10.1093/rheumatology/36.1.32. Br J Rheumatol. 1997. PMID: 9117171

4

Predisposing factors in sulphasalazine-induced systemic lupus erythematosus.

Gunnarsson I, Kanerud L, Pettersson E, Lundberg I, Lindblad S, Ringertz B. Gunnarsson I, et al. Br J Rheumatol. 1997 Oct;36(10):1089-94. doi: 10.1093/rheumatology/36.10.1089. Br J Rheumatol. 1997. PMID: 9374926

5

Development of lupus-related side-effects in patients with early RA during sulphasalazine treatment-the role of IL-10 and HLA.

Gunnarsson I, Nordmark B, Hassan Bakri A, Gröndal G, Larsson P, Forslid J, Klareskog L, Ringertz B. Gunnarsson I, et al. Rheumatology (Oxford). 2000 Aug;39(8):886-93. doi: 10.1093/rheumatology/39.8.886. Rheumatology (Oxford). 2000. PMID: 10952745

6

Cytokine production, serum levels and disease activity in systemic lupus erythematosus.

Gröndal G, Gunnarsson I, Rönnelid J, Rogberg S, Klareskog L, Lundberg I. Gröndal G, et al. Among authors: gunnarsson i. Clin Exp Rheumatol. 2000 Sep-Oct;18(5):565-70. Clin Exp Rheumatol. 2000. PMID: 11072595

7

Repeated renal biopsy in proliferative lupus nephritis--predictive role of serum C1q and albuminuria.

Gunnarsson I, Sundelin B, Heimbürger M, Forslid J, van Vollenhoven R, Lundberg I, Jacobson SH. Gunnarsson I, et al. J Rheumatol. 2002 Apr;29(4):693-9. J Rheumatol. 2002. PMID: 11950009

8

Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone.

van Vollenhoven RF, Gunnarsson I, Welin-Henriksson E, Sundelin B, Osterborg A, Jacobson SH, Klareskog L. van Vollenhoven RF, et al. Among authors: gunnarsson i. Scand J Rheumatol. 2004;33(6):423-7. doi: 10.1080/03009740410010227. Scand J Rheumatol. 2004. PMID: 15794203

9

The R620W C/T polymorphism of the gene PTPN22 is associated with SLE independently of the association of PDCD1.

Reddy MV, Johansson M, Sturfelt G, Jönsen A, Gunnarsson I, Svenungsson E, Rantapää-Dahlqvist S, Alarcón-Riquelme ME. Reddy MV, et al. Among authors: gunnarsson i. Genes Immun. 2005 Dec;6(8):658-62. doi: 10.1038/sj.gene.6364252. Genes Immun. 2005. PMID: 16052172

10

Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis.

Gunnarsson I, Sundelin B, Jónsdóttir T, Jacobson SH, Henriksson EW, van Vollenhoven RF. Gunnarsson I, et al. Arthritis Rheum. 2007 Apr;56(4):1263-72. doi: 10.1002/art.22505. Arthritis Rheum. 2007. PMID: 17393458 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

241 results

Search Page